Three Cases of Intra-familial Transmission of Hand, Foot and Mouth Disease Treated with Acyclovir

Aman Kataria^1, , Hema Chagarlamudi¹, Jordan Carbono¹, Aazim Arif¹ and Melodie Mope MD^{1, 2}

¹Florida State University College of Medicine, Orlando campus, Orlando, FL USA

²Orlando Health Physicians Associates, Orlando, FL, USA

Cite this paper

Aman Kataria, Hema Chagarlamudi, Jordan Carbono, Aazim Arif and Melodie Mope MD. Three Cases of Intra-familial Transmission of Hand, Foot and Mouth Disease Treated with Acyclovir. American Journal of Medical Case Reports. 2019; 7(9):219-222. doi: 10.12691/AJMCR-7-9-10

Abstract

Background: Hand, foot and mouth disease (HFMD) is a viral illness that presents mainly in children but also in adults with constitutional symptoms such as low-grade fever, malaise, and myalgia in addition to macular, maculopapular, or papulovesicular skin lesions on hands, feet, and mouth. No specific antiviral therapy is available for HFMD as most cases have a benign clinical course with complete resolution of symptoms and signs within 7 to 10 day. To our knowledge, three previous studies have demonstrated prompt symptomatic relief and shortened disease course after initiating treatment with acyclovir. Case Presentation: Three cases of intra-familial transmission HFMD including two young siblings (2-year-old boy and 4-year-old boy) and their 37-year-old immunocompetent mother. The diagnosis was made clinically and therapy with oral acyclovir was initiated within 24 hours of first lesion appearance for all three cases. The young siblings received oral acyclovir 200 mg four times daily, while their immunocompetent mother received acyclovir 800 mg four times daily. In the two young siblings, new lesions stopped appearing and most existing lesions showed noticeable involution after a single day of treatment. Significant reduction in pruritus and defervescence were also noted at this time. Complete resolution was achieved with three days of acyclovir therapy. The single vesicle observed on their mother showed complete resolution after a single day of treatment. Conclusion: We present three studies of HFMD successfully treated with acyclovir to demonstrate the therapeutic benefit of acyclovir for symptomatic HFMD in young children and adults. Early initiation of oral acyclovir may influence the disease course by shortening the duration and intensity of symptoms. In the case of outbreaks, in particular, acyclovir should be considered as it may offer benefit to the population at large. We recommend a randomized, controlled trial to further investigate the therapeutic role of acyclovir in HFMD.

Keywords

hand, foot and mouth disease, acyclovir, pediatric rashes, coxsackievirus

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	ALSOP J, FLEWETT TH, FOSTER JR. "Hand-foot-and-mouth disease" in Birmingham in 1959. Br Med J. 1960 Dec 10; 2(5214): 1708-11.
[2]	Kushner PG, Krebs M. Epidemiology of hand, foot, and mouth disease in a summer camp due to Coxsackie virus A16. J Am Osteopath Assoc. 1972 Nov; 72(3): 281-3.
[3]	Chang LY, Lin TY, Huang YC, Tsao KC, Shih SR, Kuo ML, Nine HC, Chung PW, Kang CM. Comparison of enterovirus 71 and coxsackievirus A16 clinical illness during Taiwan Enterovirus epidemic. 1998. Pediatr. Infect. Dis. J. 1999; 18: 1092-6.
[4]	Repass GL, Palmer WC, Stancampiano FF (September 2014). "Hand, foot, and mouth disease: Identifying and managing an acute viral syndrome". Cleve Clin J Med. 81 (9): 537-43.
[5]	Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010 Nov; 10(11): 778-90.
[6]	Aswathyraj S, Arunkumar G, Alidjinou EK, Hober D. Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy. Med Microbiol Immunol. 2016 Oct; 205(5): 397-407.
[7]	Kaminska K, Martinetti G, Lucchini R, Kaya G, Mainetti C. Coxsackievirus A6 and Hand, Foot and Mouth Disease: Three Case Reports of Familial Child-to-Immunocompetent Adult Transmission and a Literature Review. Case Rep Dermatol. 2013 Aug 7; 5(2): 203-9.
[8]	Omaña-Cepeda C, Martínez-Valverde A, del Mar Sabater-Recolons M, Jané-Salas E, Marí-Roig A, López-López J. A literature review and case report of hand, foot and mouth disease in an immunocompetent adult. BMC Res Notes. 2016 Mar 15; 9: 165.
[9]	Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick's dermatology in general medicine. 7th ed. New York: McGraw-Hill; 2008. pp. 1867-1869.
[10]	Shin JU, Oh SH, Lee JH. A Case of Hand-foot-mouth Disease in an Immunocompetent Adult. Ann Dermatol. 2010 May; 22(2): 216-8.
[11]	Faulkner CF, Godbolt AM, DeAmbrosis B, Triscott J. Hand, foot and mouth disease in an immunocompromised adult treated with aciclovir. Australas J Dermatol. 2003 Aug; 44(3): 203-6.
[12]	Chang LY, Tsao KC, Hsia SH, Shih SR, Huang CG, Chan WK, Hsu KH, Fang TY, Huang YC, Lin TY: Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA 2004; 291: 222-227.
[13]	Ślebioda Z, Dorocka-Bobkowska B. Hand, foot and mouth disease as an emerging public health problem: Case report of familial child-to-adult transmission. Dent Med Probl. 2018 Jan-Mar; 55(1): 99-104.
[14]	Shelley WB, Hashim M, Shelley ED. Acyclovir in the treatment of hand-foot-and-mouth disease. Cutis. 1996 Apr;57(4):232-4.
[15]	Lin H, Huang L, Zhou J, Lin K, Wang H, Xue X, Xia C. Efficacy and safety of interferon-α2b spray in the treatment of hand, foot, and mouth disease: a multicenter, randomized, double-blind trial. Arch Virol. 2016 Nov; 161(11):3073-80.
[16]	Florea, NR, Maglio D, Nicolau DP. Pleconaril, a novel antipicornaviral agent. Pharmacotherapy. 2003; 23(3): 339-348.
[17]	Abzug MJ, Michaels MG, Wald E, Jacobs RF, Romero JR, Sánchez PJ, Wilson G, Krogstad P, Storch GA, Lawrence R, Shelton M, Palmer A, Robinson J, Dennehy P, Sood SK, Cloud G, Jester P, Acosta EP, Whitley R, Kimberlin D; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.. A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus Sepsis. J Pediatric Infect Dis Soc. 2016 Mar; 5(1): 53-62.
[18]	Rotbart HA, Webster AD; Pleconaril Treatment Registry Group.. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis. 2001 Jan 15; 32(2): 228-35. Epub 2001 Jan 15.
[19]	Desmond RA, Accortt NA, Talley L, Villano SA, Soong SJ, Whitley RJ. Enteroviral meningitis: natural history and outcome of pleconaril therapy. Antimicrob Agents Chemother. 2006 Jul; 50(7): 2409-14.
[20]	Adhisivam B, Venkatesh C. Oseltamivir for hand, foot and mouth disease. Indian Pediatr. 2015 Aug; 52(8):716.
[21]	Nilsson EC, Jamshidi F, Johansson SM, Oberste MS, Arnberg N. Sialic acid is a cellular receptor for coxsackievirus A24 variant, an emerging virus with pandemic potential. J Virol. 2008; 82: 3061-8.
[22]	Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother. 1999 Sep; 43(9): 2109-15.
[23]	Pourianfar HR, Grollo L. Development of antiviral agents toward enterovirus 71 infection. J Microbiol Immunol Infect. 2015 Feb; 48(1): 1-8.